Rhythm Pharmaceuticals Inc logo

RYTM

Rhythm Pharmaceuticals Inc

$16.9

Earnings Summary

Revenue
$0Mn
Net Profits
$-28.97Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Rhythm Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2019. On a quarterly growth basis, Rhythm Pharmaceuticals Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Rhythm Pharmaceuticals Inc’s net profit fell -76.04% since last year same period to $-28.97Mn in the Q1 2019. On a quarterly growth basis, Rhythm Pharmaceuticals Inc has generated -13.59% fall in its net profits since last 3-months.

Net Profit Margins:

Rhythm Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2019. On a quarterly growth basis, Rhythm Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Rhythm Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.81
EPS Estimate Current Year
-0.81

Highlights

EPS Estimate Current Quarter:

Rhythm Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a 19% jump from last quarter’s estimates.

EPS Estimate Current Year:

Rhythm Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.81.

Key Ratios

Key ratios of the Rhythm Pharmaceuticals Inc post its Q4 2022 earnings

Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-0.66

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rhythm Pharmaceuticals Inc’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rhythm Pharmaceuticals Inc’s return on equity (ROE) stands at -0.66.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2018-05-14
-0.45
-0.6
-33.33%
2018-11-09
-0.46
-0.52
-13.04%
2018-08-08
-0.48
-0.52
-8.33%
2019-03-08
-0.57
-0.74
-29.82%

Company Information

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.

Organisation
Rhythm Pharmaceuticals Inc
Headquarters
222 Berkeley Street, Boston, MA, United States, 02116
Employees
177
Industry
Health Technology
CEO
Hunter Smith